quinazolines has been researched along with Adenocarcinoma, Alveolar in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 39 (53.42) | 29.6817 |
| 2010's | 34 (46.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertran-Alamillo, J; Carcereny, E; Costa, C; Gasco, A; Gimenez-Capitan, A; Jimeno, J; Karachaliou, N; Majem, M; Massuti, B; Mayo, C; Molina-Vila, MA; Moran, T; Rosell, R; Sanchez, JJ; Souglakos, J; Viteri, S; Wannesson, L | 1 |
| Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Berezo, JÁ; de la Cruz, V; Sanz Rubiales, A; Torres, MÁ | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Hong, SE; Jang, YS; Jeong, W; Jo, YJ; Kim, H; Kim, J; Lee, GR; Lee, HI; Lee, HJ; Lee, J; Lee, JS; Oh, SH | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM | 1 |
| Camidge, DR; Erickson, TM; Koeppe, JR; Miller, YE; Stuart, RW | 1 |
| Calabrò, E; De Marinis, F; Fabbri, A; Marchianò, A; Novello, S; Orsenigo, M; Pastorino, U; Sozzi, G; Tamborini, E | 1 |
| Baudrin, L; Cadranel, J; Milleron, B; Morere, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Souquet, PJ | 1 |
| Antoine, M; Baudrin, L; Cadranel, J; Isaac-Sibille, S; Lebitasy, MP; Longchampt, E; Neuville, A; Poulot, V; Pradere, M; Wislez, M | 1 |
| Garfield, DH; West, HL | 1 |
| Ma, PC; Manson, GV | 1 |
| Neal, JW | 1 |
| Ayabe, E; Endo, M; Horie, Y; Kaira, K; Kondo, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishihara, K; Kaji, R; Katakami, N; Nishimura, T; Takahashi, Y; Tomii, K | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Fabian, P; Lakomý, R; Nemecek, R; Slabý, O; Stanková, M; Svoboda, M; Vyzula, R | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Chattopadhyay, S; Cohen, MH; Johnson, JR; Justice, R; Pazdur, R; Sridhara, R; Tang, S | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Chen, J; Chu, BB; Deng, J; Fang, HM; Fang, WJ; Mou, HB; Qian, J; Teng, LS; Wu, DP; Xu, N; Zhang, XC | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M | 1 |
| Agelaki, S; Georgoulias, V; Giassas, S; Kentepozidis, N; Kotsakis, A; Pallis, AG; Papakotoulas, P; Tryfonidis, K; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| McIvor, RA; Popat, N; Raghavan, N | 1 |
| Egawa, K; Matsushita, H; Miura, H; Osawa, T; Takahashi, T; Tsubouchi, Y; Yuyama, K | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
| El-Modir, A; Stevenson, R | 1 |
| Bunn, PA; Casás-Selves, M; Chan, DC; DeGregori, J; Gao, D; Helfrich, BA; Kim, J; Porter, CC; Scarborough, HA; Tan, AC; Zhang, Z | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P | 1 |
| Giuliani, J; Marzola, M | 1 |
| Aono, Y; Azuma, M; Kanematsu, T; Miki, T; Sone, S; Uehara, H; Yamamoto, A; Yano, S | 1 |
| Chang, GC; Chiang, CD; Huang, CM; Wang, NS; Yang, TY | 1 |
| Green, MR | 1 |
| Argiris, A; Mittal, N | 1 |
| Chansky, K; Crowley, J; Davies, AM; Franklin, WA; Gandara, DR; Gumerlock, PH; Hirsch, FR; Lau, DH; West, H | 1 |
| Bayle, S; Daniel, C; Descourt, R; Gouva, S; Robinet, G | 1 |
| Li, LY; Wang, SL; Zhang, XT | 1 |
| Feinstein, MB; Gomez, JE; Kris, MG; Milton, DT | 1 |
| Ahn, SJ; Baek, SM; Jeong, JY; Kim, KS; Kim, YC; Kim, YH; Kim, YI; Lim, SC; Na, KJ; Park, CM; Park, CS; Park, KO | 1 |
| Coulon, C; Gandara, D; Geraghty, E; Laptalo, L; Lau, D; Seibert, A | 1 |
| Edelman, MJ | 1 |
| Anderson, H; Bebb, G; Ho, C; Laskin, J; Melosky, B; Murray, N | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Soda, H | 1 |
| Bunn, PA; Crowley, J; Franklin, WA; Gandara, DR; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| Brom, R; Candelaria, M; Duenas-Gonzalez, A; Meza, F; Taja-Chayeb, L; Trejo-Becerril, C | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T | 1 |
| Anderson, F; Bebb, G; Davis, J; Ho, C; Murray, N | 1 |
| Cody, DD; Dackor, J; Fujimoto, N; Hanna, AE; Herbst, R; Iwanaga, K; Kalyankrishna, S; Kurie, JM; Massarelli, E; Minna, JD; Peyton, M; Price, RE; Sato, M; Shay, JW; Tang, X; Threadgill, DW; Wislez, M; Wistuba, II; Zhang, J | 1 |
| Ballas, M; Dennis, PA; Egilsson, V; Steinberg, SM; Tsurutani, J | 1 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Gumerlock, PH; Lau, DH; McCoy, J; Vance, R; West, HL | 1 |
| Al-Hashem, R; Bronson, RT; Chen, L; Chirieac, LR; Jänne, PA; Ji, H; Johnson, BE; Kim, W; Kobayashi, S; Li, D; Mahmood, U; McNamara, K; Mitchell, A; Padera, R; Shapiro, GI; Sharpless, NE; Shimamura, T; Sun, Y; Tenen, D; Weissleder, R; Wong, KK | 1 |
| Arteaga, CL | 1 |
| Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH | 1 |
| Breau, JL; Brechot, JM; Chouahnia, K; Des-Guetz, G; Morere, JF; Saintigny, P | 1 |
| Hirsch, FR | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Bunn, PA; Dziadziuszko, R; Hirsch, FR; Jassem, J; Limon, J; Rzyman, W; Siemiatkowska, A; Varella-Garcia, M | 1 |
| Basti, S; Jampol, LM; Zhang, G | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Milleron, B; Wislez, M | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Goya, S; Kawase, I; Kijima, T; Kumagai, T; Matsuoka, H; Minami, S; Osaki, T; Suzuki, M; Tachibana, I; Takeda, Y; Ueda, K; Yokota, S; Yoshida, M | 1 |
| Ebi, N; Fukuoka, J; Fukuoka, M; Hirashima, T; Ichinose, Y; Kashii, T; Katakami, N; Kudoh, S; Negoro, S; Nishimura, T; Okamoto, I; Satoh, T; Sawa, T; Shibata, K; Shimizu, E; Tamura, K | 1 |
| Carbone, DP; Heelan, RT; Heller, G; Herbst, RS; Johnson, DH; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Patel, JD; Riely, GJ; Sandler, AB; Tsao, A; Zakowski, MF | 1 |
6 review(s) available for quinazolines and Adenocarcinoma, Alveolar
| Article | Year |
|---|---|
[EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Quinazolines; Signal Transduction | 2004 |
Computer-assisted image analysis of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Quinazolines; Remission Induction; Tomography, X-Ray Computed | 2005 |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction | 2006 |
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2007 |
19 trial(s) available for quinazolines and Adenocarcinoma, Alveolar
| Article | Year |
|---|---|
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transcription Factors | 2010 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines | 2008 |
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2008 |
48 other study(ies) available for quinazolines and Adenocarcinoma, Alveolar
| Article | Year |
|---|---|
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Endodeoxyribonucleases; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; LIM Domain Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult | 2013 |
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Bronchi; Bronchial Diseases; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Effective killing of cancer cells and regression of tumor growth by K27 targeting sulfiredoxin.
Topics: A549 Cells; Acetylcysteine; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; beta-Alanine; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Epithelial Cells; Female; Gene Expression; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mitochondria; Molecular Targeted Therapy; Oxidative Stress; Oxidoreductases Acting on Sulfur Group Donors; Quinazolines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome | 2009 |
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Chronic Disease; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Female; HIV; HIV Infections; Humans; Lung Diseases, Interstitial; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2008 |
Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Hyperplasia; Lung; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Remission Induction; Tomography, X-Ray Computed | 2009 |
Bronchioloalveolar carcinoma: not as easy as "BAC".
Topics: Adenocarcinoma, Bronchiolo-Alveolar; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Biomarkers, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
Severe bronchorrhea in a patient with bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Biopsy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sputum; Tomography, X-Ray Computed | 2012 |
[A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |
Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Onycholysis; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2011 |
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; Tankyrases; Wnt Proteins; Xenograft Model Antitumor Assays | 2012 |
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Quinazolines; Radiography; Sputum | 2003 |
Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
Targeting targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2004 |
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
[Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
[Gefitinib for advanced bronchioloalveolar carcinoma].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2004 |
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sputum | 2005 |
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; North America; Predictive Value of Tests; Quinazolines; Retrospective Studies; White People | 2005 |
Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Dyspnea; Female; Gefitinib; Humans; Lung Neoplasms; Mucins; Quinazolines | 2005 |
Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2005 |
Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Neoplasms, Glandular and Epithelial; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured; Tyrosine | 2005 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Structure, Tertiary; Quinazolines; Quinolines | 2006 |
Synchronous multiple primary lung cancers with different response to gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Quinazolines; Tomography, X-Ray Computed | 2006 |
[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Meningitis; Middle Aged; Neoplasm Proteins; Paclitaxel; Palliative Care; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Vinblastine; Vinorelbine | 2006 |
K-ras mutations in lung cancer: the "mysterious mutation".
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Topics: Acneiform Eruptions; Adenocarcinoma, Bronchiolo-Alveolar; Aged, 80 and over; Antineoplastic Agents; Blepharitis; Carcinoma, Small Cell; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Retrospective Studies | 2007 |
Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Remission Induction | 2007 |